Unique ID issued by UMIN | UMIN000008913 |
---|---|
Receipt number | R000010454 |
Scientific Title | Comparison of the effects of celiprolol and bisoprolol on central BP and measures of atherosclerosis in hypertensive patients. |
Date of disclosure of the study information | 2012/09/13 |
Last modified on | 2013/09/14 08:51:12 |
Comparison of the effects of celiprolol and bisoprolol on central BP and measures of atherosclerosis in hypertensive patients.
Comparative study between celiprolol and bisoprolol (CB trial)
Comparison of the effects of celiprolol and bisoprolol on central BP and measures of atherosclerosis in hypertensive patients.
Comparative study between celiprolol and bisoprolol (CB trial)
Japan |
Hypertensive patients.
Cardiology |
Others
NO
To compare the effects of two different types of beta blockers, celiprolol and bisoprolol, on central BP, endotherial function, autonomic nerve functions, and glucose and lipid metabolism in hypertensive patients.
Efficacy
Confirmatory
Pragmatic
Not applicable
1.Effects on casual blood pressure
Extent of BP reduction (SBP, DBP, and mean BP)
2.Ambulatory BP
Extent of BP reduction (SBP, DBP, and mean BP)
3.Pulse wave velocity (PWV), pulse wave analysis (PWA), augmentation index (AI) , central BP
4.The effects on the measures of cardiac and renal target organ damage (urinary microalbumin, hsCRP, hsTroponin T, BNP, NT-proBNP)
5.Effects on glucose and lipid
6.Effects on the measures of insulin resistance (HOMA-R)
7.Effects on autonomic nervous functions (CVRR, BRS etc)
Adverse effects, and safety measures.
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
2
Treatment
Medicine |
Administer celiprolol 100mg from the beginning and titrated up to 200mg for a total of 12 weeks. If the clinic BP is 140/90mmHg or more at the time of 4th week, the dose will be increased from 100 to 200mg.
Administer bisoprolol 2.5mg from the beginning and titrated up to 5mg for a total of 12 weeks. If the clinic BP is 140/90mmHg or more at the time of 4th week, the dose will be increased from 2.5 to 5mg.
25 | years-old | <= |
Not applicable |
Male and Female
1.The Age>=25 years
2.Hypertensive patients
3.Patients who are not taking beta blockers
4. Secondary hypertension will be included
1.Patients with malignant hypertension
2.Decompensated heart failure (NYHA III or IV)
3. Malignancy needing treatment
4.Hepatic or renal disease (serum creatinine >3.0mg/dl or under hemodialysis)
5.Those who had had severe side effects with beta blockers
6.Those with contraindication for beta blockers (bronchial asthma, bradycardia, vasospastic angina, pregnant women etc.)
7.Those with hyper- or hypoglycemic attack
8. Those with dementia from whom we cannot obtain informed consent.
100
1st name | |
Middle name | |
Last name | Kazuo Eguchi |
Jichi Medical University School of Medicine
Division of Cardiovascular Medicine,Department of Medicine
3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
0285-58-7344
1st name | |
Middle name | |
Last name | Kazuo Eguchi |
Jichi Medical University School of Medicine
Division of Cardiovascular Medicine,Department of Medicine
3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
0285-58-7344
ke112@jichi.ac.jp
Jichi Medical University School of Medicine
Jichi Medical University School of Medicine
Self funding
International University of Health and Welfare Hospital
NO
2012 | Year | 09 | Month | 13 | Day |
Unpublished
Completed
2011 | Year | 02 | Month | 03 | Day |
2011 | Year | 02 | Month | 04 | Day |
2013 | Year | 07 | Month | 31 | Day |
2012 | Year | 09 | Month | 13 | Day |
2013 | Year | 09 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010454
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |